253 related articles for article (PubMed ID: 29581279)
1. Reduction of lipid accumulation rescues Bietti's crystalline dystrophy phenotypes.
Hata M; Ikeda HO; Iwai S; Iida Y; Gotoh N; Asaka I; Ikeda K; Isobe Y; Hori A; Nakagawa S; Yamato S; Arita M; Yoshimura N; Tsujikawa A
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):3936-3941. PubMed ID: 29581279
[TBL] [Abstract][Full Text] [Related]
2. PSCs Reveal PUFA-Provoked Mitochondrial Stress as a Central Node Potentiating RPE Degeneration in Bietti's Crystalline Dystrophy.
Zhang Z; Yan B; Gao F; Li Q; Meng X; Chen P; Zhou L; Deng W; Li C; Xu W; Han S; Feng H; Li Y; Chen J; Yin Z; Liao C; Tse HF; Xu A; Lian Q
Mol Ther; 2020 Dec; 28(12):2642-2661. PubMed ID: 32755565
[TBL] [Abstract][Full Text] [Related]
3. AAV-mediated gene-replacement therapy restores viability of BCD patient iPSC derived RPE cells and vision of Cyp4v3 knockout mice.
Jia R; Meng X; Chen S; Zhang F; Du J; Liu X; Yang L
Hum Mol Genet; 2023 Jan; 32(1):122-138. PubMed ID: 35925866
[TBL] [Abstract][Full Text] [Related]
4. CYP4V2 in Bietti's crystalline dystrophy: ocular localization, metabolism of ω-3-polyunsaturated fatty acids, and functional deficit of the p.H331P variant.
Nakano M; Kelly EJ; Wiek C; Hanenberg H; Rettie AE
Mol Pharmacol; 2012 Oct; 82(4):679-86. PubMed ID: 22772592
[TBL] [Abstract][Full Text] [Related]
5. In vivo genome editing via CRISPR/Cas9-mediated homology-independent targeted integration for Bietti crystalline corneoretinal dystrophy treatment.
Meng X; Jia R; Zhao X; Zhang F; Chen S; Yu S; Liu X; Dou H; Feng X; Zhang J; Wang N; Xu B; Yang L
Nat Commun; 2024 May; 15(1):3773. PubMed ID: 38710738
[TBL] [Abstract][Full Text] [Related]
6. Identification of CYP4V2 mutation in 36 Chinese families with Bietti crystalline corneoretinal dystrophy.
Yin X; Yang L; Chen N; Cui H; Zhao L; Feng L; Li A; Zhang H; Ma Z; Li G
Exp Eye Res; 2016 May; 146():154-162. PubMed ID: 26971461
[TBL] [Abstract][Full Text] [Related]
7. A novel mutation in the CYP4V2 gene in a Chinese patient with Bietti's crystalline dystrophy.
Song Y; Mo G; Yin G
Int Ophthalmol; 2013 Jun; 33(3):269-76. PubMed ID: 23242590
[TBL] [Abstract][Full Text] [Related]
8. Genetics of Bietti Crystalline Dystrophy.
Ng DS; Lai TY; Ng TK; Pang CP
Asia Pac J Ophthalmol (Phila); 2016; 5(4):245-52. PubMed ID: 27228076
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of Lipid Droplets in a Novel Bietti Crystalline Dystrophy Zebrafish Model With Impaired PPARα Pathway.
Gao P; Jia D; Li P; Huang Y; Hu H; Sun K; Lv Y; Chen X; Han Y; Zhang Z; Ren X; Wang Q; Liu F; Tang Z; Liu M
Invest Ophthalmol Vis Sci; 2022 May; 63(5):32. PubMed ID: 35616930
[TBL] [Abstract][Full Text] [Related]
10. Detailed functional and structural phenotype of Bietti crystalline dystrophy associated with mutations in CYP4V2 complicated by choroidal neovascularization.
Fuerst NM; Serrano L; Han G; Morgan JI; Maguire AM; Leroy BP; Kim BJ; Aleman TS
Ophthalmic Genet; 2016 Dec; 37(4):445-452. PubMed ID: 27028354
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel CYP4V2 gene mutations in 92 Chinese families with Bietti's crystalline corneoretinal dystrophy.
Meng XH; Guo H; Xu HW; Li QY; Jin X; Bai Y; Li SY; Yin ZQ
Mol Vis; 2014; 20():1806-14. PubMed ID: 25593508
[TBL] [Abstract][Full Text] [Related]
12. Presence of corneal crystals confirms an unusual presentation of Bietti's retinal dystrophy.
Song WK; Clouston P; MacLaren RE
Ophthalmic Genet; 2019 Oct; 40(5):461-465. PubMed ID: 31638456
[No Abstract] [Full Text] [Related]
13. Longitudinal characterisation of function and structure of Bietti crystalline dystrophy: report on a novel homozygous mutation in
Lockhart CM; Smith TB; Yang P; Naidu M; Rettie AE; Nath A; Weleber R; Kelly EJ
Br J Ophthalmol; 2018 Feb; 102(2):187-194. PubMed ID: 28698241
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel CYP4V2 genotypes associated with Bietti crystalline dystrophy and atypical anterior segment phenotypes in Spanish patients.
García-García GP; Martínez-Rubio M; Moya-Moya MA; Pérez-Santonja JJ; Escribano J
Acta Ophthalmol; 2018 Nov; 96(7):e865-e873. PubMed ID: 29691984
[TBL] [Abstract][Full Text] [Related]
15. CYP4V2 fatty acid omega hydroxylase, a druggable target for the treatment of metabolic associated fatty liver disease (MAFLD).
Osborne N; Leahy C; Lee YK; Rote P; Song BJ; Hardwick JP
Biochem Pharmacol; 2022 Jan; 195():114841. PubMed ID: 34798124
[TBL] [Abstract][Full Text] [Related]
16. Genotype and Ocular Phenotype in Sixteen Chinese Patients with Bietti Corneoretinal Crystalline Dystrophy.
Dai H; Zhang Y; Li R; Li Y; Li G
Curr Eye Res; 2022 Mar; 47(3):436-442. PubMed ID: 34724870
[TBL] [Abstract][Full Text] [Related]
17. Novel CYP4V2 gene mutation in a Mexican patient with Bietti's crystalline corneoretinal dystrophy.
Zenteno JC; Ayala-Ramirez R; Graue-Wiechers F
Curr Eye Res; 2008 Apr; 33(4):313-8. PubMed ID: 18398705
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular findings in three Lebanese families with Bietti crystalline dystrophy: report on a novel mutation.
Haddad NM; Waked N; Bejjani R; Khoueir Z; Chouery E; Corbani S; Mégarbané A
Mol Vis; 2012; 18():1182-8. PubMed ID: 22605929
[TBL] [Abstract][Full Text] [Related]
19. [Progress in the studies of molecular genetics in Bietti crystalline corneoretinal dystrophy].
Xu F; Sui RF; Dong FT
Zhonghua Yan Ke Za Zhi; 2012 Oct; 48(10):948-51. PubMed ID: 23302251
[TBL] [Abstract][Full Text] [Related]
20. Sustained Release Formulation of Hydroxypropyl-β-cyclodextrin Eye Drops Using Xanthan Gum.
Higashi T; Goto T; Onodera R; Hirotsu T; Ikeda HO; Motoyama K
Chem Pharm Bull (Tokyo); 2024; 72(4):381-384. PubMed ID: 38616116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
